Nautilus Biotechnology

Biotech tools / proteomicsUSA

New to Unitard

📉 Public < $1B

Peak $1.5 BillionToday

−73%

from peak

🦄
Became a unicorn
2021
📈
Peak valuation
$1.5 Billion ’21
💔
Became a Unitard
2022
💸
Last valuation
~$412M

Current status

Public (Nasdaq: NAUT); product launch delayed to 2026, 16% layoffs (2025)

Live · NAUT· NasdaqCM

as of 2026-10-23

$3.24▲ 57.28% today

≈ $412 Million market cap · −72.6% from peak

The rise & fall

5 moments · 2016–2025

The key moments.

2016

Founded to map the human proteome

Isilon co-founder Sujal Patel and Stanford scientist Parag Mallick set out to read every protein with a single-molecule platform.

GeekWire

Jun 2021

The peak: a ~$1.5B SPAC debut$1.5B

Merges with Perceptive Advisors' Arya Sciences Acquisition Corp III and trades above $10 a share — before the platform has shipped.

Businesswire

2022

Slips out of the club

The stock sinks with the rest of the de-SPAC class of 2021, falling below a $1B value on its way to a 90%-plus drawdown.

GeekWire

2022–24

The launch keeps receding

Commercialization targets slip year after year — eventually to late 2026 — while losses mount.

GeekWire

2025

16% of staff cut

With the platform still unlaunched and the market cap around $105M, Nautilus lays off 16% of its workforce.

GeekWire

Today

Still in the club — and still trading

Live · NAUT · NasdaqCMas of 2026-10-23

$3.24▲ 57.28% today≈ $412M cap · −72.6% from peak

How it happened

Nautilus Biotechnology aimed to map the entire human proteome with a single-molecule protein-analysis platform, and went public in June 2021 via a SPAC merger with Perceptive Advisors' Arya Sciences Acquisition Corp III, trading above $10 a share for a valuation over $1B.

The product proved hard to commercialize: launch timelines slipped repeatedly (now targeted for late 2026), losses mounted and the stock fell more than 90%. By 2025 Nautilus had cut 16% of staff and was worth only around $100M — a fraction of its debut.

A small set of Glassdoor reviews noted leadership gaps and limited career growth at the proteomics firm.

Employee accounts paraphrase anonymous, unverified reviews posted publicly on Glassdoor ↗. See our methodology.

Source: Businesswire / GeekWire / SEC (SPAC merger with Arya Sciences Acquisition Corp III, closed June 2021, traded >$10/share at >$1B; ~$105M market cap 2025; commercial platform delayed to 2026; 16% layoffs)

Founders

Sujal Patel
Co-founder & CEO (also Isilon founder)
Still there — Founder, CEOLinkedIn ↗
Parag Mallick
co-founder
Now Associate Professor at Stanford UniversityLinkedIn ↗